STOCK TITAN

[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

United Therapeutics (UTHR) disclosed an insider update: a director filed a Form 4 noting a transfer of 225 shares of common stock on 09/09/2024 from a jointly held account to an account in which he has no beneficial interest. The entry shows Transaction Code G at a reported price of $0.00.

The filing states the transfer was done without the reporting person’s knowledge and was discovered recently, which caused subsequent Forms 4 to overstate his beneficial holdings. Following the correction, the director reports 4,640 shares held directly.

United Therapeutics (UTHR) ha comunicato un aggiornamento da insider: un membro del consiglio ha presentato un Modulo 4 indicando un trasferimento di 225 azioni di azioni ordinarie in data 09/09/2024 da un conto cointestato a un conto in cui non detiene alcun interesse beneficiario. L'inserimento mostra Codice di Transazione G ad un prezzo riportato di $0.00.

La dichiarazione afferma che il trasferimento è stato effettuato senza la conoscenza della persona che ha presentato la comunicazione ed è stato scoperto recentemente, il che ha causato che i successivi Moduli 4 sovrastimassero le sue partecipazioni beneficiarie. Dopo la correzione, il direttore riporta 4.640 azioni detenute direttamente.

United Therapeutics (UTHR) divulgó una actualización de insider: un director presentó un Formulario 4 que indica un traslado de 225 acciones de acciones ordinarias el 09/09/2024 desde una cuenta de titularidad conjunta a una cuenta en la que no tiene interés beneficioso. La entrada muestra Código de Transacción G con un precio reportado de $0.00.

La declaración dice que la transferencia se realizó sin el conocimiento de la persona que presentó el informe y que se descubrió recientemente, lo que provocó que los Form 4 siguientes sobrestimaran sus participaciones beneficiosas. Tras la corrección, el director informa 4,640 acciones que posee directamente.

United Therapeutics (UTHR)은 내부자 업데이트를 공개했습니다: 이사 한 명이 225주의 보통주를 2024년 9월 9일에 공동으로 보유한 계정에서 그가 실질적인 이익을 보유하지 않은 계정으로 이전했다고 Form 4를 제출했습니다. 항목은 거래 코드 G를 보이며 보고된 가격은 $0.00입니다.

신고 내용에 따르면 이 전송은 보고자도 모르는 사이에 이루어졌고 최근에 발견되어 이후의 Form 4가 그의 실질 보유 주식을 과대 기재하게 만들었다고 합니다. 수정 후 이사는 직접 보유한 주식 수를 4,640주로 보고합니다.

United Therapeutics (UTHR) a publié une mise à jour interne: un administrateur a déposé un Form 4 indiquant un transfert de 225 actions d'actions ordinaires le 09/09/2024 d'un compte détenu conjointement vers un compte dans lequel il n'a aucun intérêt bénéficiaire. L'entrée affiche le Code de Transaction G à un prix indiqué de $0.00.

Le dossier précise que le transfert a été effectué sans la connaissance de la personne qui a déposé le rapport et a été découvert récemment, ce qui a entraîné une surestimation de ses participations bénéficiaires dans les formulaires 4 suivants. Après correction, le directeur déclare 4 640 actions détenues directement.

United Therapeutics (UTHR) veröffentlichte ein Insider-Update: Ein Vorstandsmitglied reichte ein Formular 4 ein, das einen Transfer von 225 Aktien Stammaktien am 09.09.2024 von einem gemeinsam geführten Konto auf ein Konto, an dem er kein wirtschaftliches Interesse hat, angibt. Der Eintrag zeigt Transaktionscode G zu einem berichteten Preis von $0.00.

Die Einreichung besagt, dass der Transfer ohne Wissen der meldenden Person erfolgt ist und kürzlich entdeckt wurde, was dazu führte, dass nachfolgende Formulare 4 seine wirtschaftlichen Beteiligungen überbewerteten. Nach der Korrektur meldet der Direktor 4.640 Aktien, die er direkt hält.

United Therapeutics (UTHR) كشفت عن تحديث داخلي: قام أحد أعضاء مجلس الإدارة بتقديم نموذج 4 يشير إلى تحويل 225 سهماً من الأسهم العادية في 09/09/2024 من حساب مشترك إلى حساب لا يملك فيه أي مصلحة فاعلة. تُظهر الإدخال رمز المعاملة G بسعر مُبلغ عنه $0.00.

تنص الإيداع أن النقل تم بلا معرفة الشخص الذي قدم الإبلاغ وُاكتشف مؤخرًا، مما أدى إلى أن تتضخم ملكيته المفترضة في النماذج 4 اللاحقة. بعد التصحيح، يذكر المدير 4,640 سهمًا مملوكة مباشرةً له.

Positive
  • None.
Negative
  • None.

Insights

Routine insider correction; no cash consideration reported.

This Form 4 records a 225-share transfer on 09/09/2024 coded G, with a reported price of $0.00. Code G typically denotes a bona fide gift or similar transfer without consideration. The filer indicates the transfer was discovered recently and that later Forms 4 had overstated holdings.

Post-update, the director lists 4,640 shares held directly. There is no issuer cash flow in this entry and no change to company operations is implied. The impact is administrative; actual market effects depend on whether any future transactions are reported.

United Therapeutics (UTHR) ha comunicato un aggiornamento da insider: un membro del consiglio ha presentato un Modulo 4 indicando un trasferimento di 225 azioni di azioni ordinarie in data 09/09/2024 da un conto cointestato a un conto in cui non detiene alcun interesse beneficiario. L'inserimento mostra Codice di Transazione G ad un prezzo riportato di $0.00.

La dichiarazione afferma che il trasferimento è stato effettuato senza la conoscenza della persona che ha presentato la comunicazione ed è stato scoperto recentemente, il che ha causato che i successivi Moduli 4 sovrastimassero le sue partecipazioni beneficiarie. Dopo la correzione, il direttore riporta 4.640 azioni detenute direttamente.

United Therapeutics (UTHR) divulgó una actualización de insider: un director presentó un Formulario 4 que indica un traslado de 225 acciones de acciones ordinarias el 09/09/2024 desde una cuenta de titularidad conjunta a una cuenta en la que no tiene interés beneficioso. La entrada muestra Código de Transacción G con un precio reportado de $0.00.

La declaración dice que la transferencia se realizó sin el conocimiento de la persona que presentó el informe y que se descubrió recientemente, lo que provocó que los Form 4 siguientes sobrestimaran sus participaciones beneficiosas. Tras la corrección, el director informa 4,640 acciones que posee directamente.

United Therapeutics (UTHR)은 내부자 업데이트를 공개했습니다: 이사 한 명이 225주의 보통주를 2024년 9월 9일에 공동으로 보유한 계정에서 그가 실질적인 이익을 보유하지 않은 계정으로 이전했다고 Form 4를 제출했습니다. 항목은 거래 코드 G를 보이며 보고된 가격은 $0.00입니다.

신고 내용에 따르면 이 전송은 보고자도 모르는 사이에 이루어졌고 최근에 발견되어 이후의 Form 4가 그의 실질 보유 주식을 과대 기재하게 만들었다고 합니다. 수정 후 이사는 직접 보유한 주식 수를 4,640주로 보고합니다.

United Therapeutics (UTHR) a publié une mise à jour interne: un administrateur a déposé un Form 4 indiquant un transfert de 225 actions d'actions ordinaires le 09/09/2024 d'un compte détenu conjointement vers un compte dans lequel il n'a aucun intérêt bénéficiaire. L'entrée affiche le Code de Transaction G à un prix indiqué de $0.00.

Le dossier précise que le transfert a été effectué sans la connaissance de la personne qui a déposé le rapport et a été découvert récemment, ce qui a entraîné une surestimation de ses participations bénéficiaires dans les formulaires 4 suivants. Après correction, le directeur déclare 4 640 actions détenues directement.

United Therapeutics (UTHR) veröffentlichte ein Insider-Update: Ein Vorstandsmitglied reichte ein Formular 4 ein, das einen Transfer von 225 Aktien Stammaktien am 09.09.2024 von einem gemeinsam geführten Konto auf ein Konto, an dem er kein wirtschaftliches Interesse hat, angibt. Der Eintrag zeigt Transaktionscode G zu einem berichteten Preis von $0.00.

Die Einreichung besagt, dass der Transfer ohne Wissen der meldenden Person erfolgt ist und kürzlich entdeckt wurde, was dazu führte, dass nachfolgende Formulare 4 seine wirtschaftlichen Beteiligungen überbewerteten. Nach der Korrektur meldet der Direktor 4.640 Aktien, die er direkt hält.

United Therapeutics (UTHR) كشفت عن تحديث داخلي: قام أحد أعضاء مجلس الإدارة بتقديم نموذج 4 يشير إلى تحويل 225 سهماً من الأسهم العادية في 09/09/2024 من حساب مشترك إلى حساب لا يملك فيه أي مصلحة فاعلة. تُظهر الإدخال رمز المعاملة G بسعر مُبلغ عنه $0.00.

تنص الإيداع أن النقل تم بلا معرفة الشخص الذي قدم الإبلاغ وُاكتشف مؤخرًا، مما أدى إلى أن تتضخم ملكيته المفترضة في النماذج 4 اللاحقة. بعد التصحيح، يذكر المدير 4,640 سهمًا مملوكة مباشرةً له.

United Therapeutics (UTHR) 披露了一项内部人士更新:一名董事提交的 Form 4 指出在 2024/09/09225 股 普通股从共同持有的账户转移到他没有实际受益的账户。该条目显示 交易代码 G,报告的价格为 $0.00

申报称该转移在汇报人未知的情况下进行,最近才被发现,这导致后续的 Form 4 高估了他的实际持股。纠正后,董事报告直接持有 4,640 股

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CAUSEY CHRISTOPHER

(Last) (First) (Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MD 20910

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/09/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/09/2024(1) G 225 D $0.00 4,640(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This Form 4 reports the transfer of 225 shares of common stock on September 9, 2024, from an account jointly held by the reporting person and his son, to an account in which the reporting person has no beneficial interest. This transfer was done without the knowledge of the reporting person, and was discovered recently. As a result of this omission, the amounts of securities beneficially owned reported in subsequent Forms 4 by the reporting person were overstated.
2. Total reported as of the date of filing, and takes into account transactions that have occurred following the date of the original transaction reported on this Form 4.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney 10/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
United Therapeutics Corp.

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Latest SEC Filings

UTHR Stock Data

18.93B
44.43M
1.77%
99.51%
5.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SILVER SPRING